These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36909046)

  • 1. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure.
    Choday S; Ravi N; Parisapogu A; Ojinna BT; Sherpa ML
    Cureus; 2023 Feb; 15(2):e34687. PubMed ID: 36909046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review.
    Fonseca-Correa JI; Correa-Rotter R
    Front Med (Lausanne); 2021; 8():777861. PubMed ID: 34988095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
    Hou YC; Zheng CM; Yen TH; Lu KC
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
    Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
    Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
    Xu D; Chandler O; Wee C; Ho C; Affandi JS; Yang D; Liao X; Chen W; Li Y; Reid C; Xiao H
    Front Med (Lausanne); 2021; 8():712671. PubMed ID: 34497814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
    Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V
    Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Communication by SGLT2 Inhibition.
    Billing AM; Kim YC; Gullaksen S; Schrage B; Raabe J; Hutzfeldt A; Demir F; Kovalenko E; Lassé M; Dugourd A; Fallegger R; Klampe B; Jaegers J; Li Q; Kravtsova O; Crespo-Masip M; Palermo A; Fenton RA; Hoxha E; Blankenberg S; Kirchhof P; Huber TB; Laugesen E; Zeller T; Chrysopoulou M; Saez-Rodriguez J; Magnussen C; Eschenhagen T; Staruschenko A; Siuzdak G; Poulsen PL; Schwab C; Cuello F; Vallon V; Rinschen MM
    Circulation; 2024 Mar; 149(11):860-884. PubMed ID: 38152989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.
    Pradhan A; Vohra S; Vishwakarma P; Sethi R
    J Family Med Prim Care; 2019 Jun; 8(6):1855-1862. PubMed ID: 31334145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
    Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice.
    Erdem S; Titus A; Patel D; Patel NN; Sattar Y; Glazier J; Alraies MC
    Cureus; 2023 Apr; 15(4):e37310. PubMed ID: 37182087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    Dyck JRB; Sossalla S; Hamdani N; Coronel R; Weber NC; Light PE; Zuurbier CJ
    J Mol Cell Cardiol; 2022 Jun; 167():17-31. PubMed ID: 35331696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment.
    Rizzo MR; Di Meo I; Polito R; Auriemma MC; Gambardella A; di Mauro G; Capuano A; Paolisso G
    Pharmacol Res; 2022 Feb; 176():106062. PubMed ID: 35017046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.
    Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.